KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Sarepta Therapeutics (SRPT) over the last 15 years, with Q3 2025 value amounting to $2.2 billion.

  • Sarepta Therapeutics' Total Liabilities fell 864.05% to $2.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 billion, marking a year-over-year decrease of 864.05%. This contributed to the annual value of $2.4 billion for FY2024, which is 125.53% up from last year.
  • According to the latest figures from Q3 2025, Sarepta Therapeutics' Total Liabilities is $2.2 billion, which was down 864.05% from $2.3 billion recorded in Q2 2025.
  • Sarepta Therapeutics' Total Liabilities' 5-year high stood at $2.7 billion during Q4 2022, with a 5-year trough of $2.2 billion in Q3 2025.
  • Its 5-year average for Total Liabilities is $2.3 billion, with a median of $2.3 billion in 2025.
  • Per our database at Business Quant, Sarepta Therapeutics' Total Liabilities skyrocketed by 2429.07% in 2022 and then plummeted by 1394.19% in 2023.
  • Sarepta Therapeutics' Total Liabilities (Quarter) stood at $2.2 billion in 2021, then rose by 23.58% to $2.7 billion in 2022, then dropped by 12.33% to $2.4 billion in 2023, then increased by 1.26% to $2.4 billion in 2024, then decreased by 10.76% to $2.2 billion in 2025.
  • Its Total Liabilities was $2.2 billion in Q3 2025, compared to $2.3 billion in Q2 2025 and $2.3 billion in Q1 2025.